SEC Takes Action Against Cassava Sciences and Executives for Deceptive Alzheimer’s Drug Claims
The U.S. Securities and Exchange Commission (SEC) has charged Cassava Sciences, Inc., along with its founder and former CEO Remi Barbier and former Senior Vice President of Neuroscience Dr. Lindsay Burns, for misleading investors about the efficacy of a Phase 2 clinical trial for their Alzheimer’s disease therapeutic. The charges stem from misleading statements made in September 2020, resulting in over $40 million in penalties to settle the allegations.